 GlaxoSmithKline plc NYSE: GSK has agreed to acquire Sierra Oncology Inc NASDAQ: SRRA for 55 per share in cash, representing an approximate total equity value of 1.9 billion 1.5 billion. Sierras momelotinib complements GSKs Blenrep belantamab. 